药品审批的监管事务和监管要求回顾

Kishore Bandarapalle, R. K. Kumarachari, Kamasani Teja Sri, Boyalapalli Neeraja, Chejarla Likhitha, Krishna Chaitanya, C. Y. Bhargavi
{"title":"药品审批的监管事务和监管要求回顾","authors":"Kishore Bandarapalle, R. K. Kumarachari, Kamasani Teja Sri, Boyalapalli Neeraja, Chejarla Likhitha, Krishna Chaitanya, C. Y. Bhargavi","doi":"10.26452/fjphs.v4i1.550","DOIUrl":null,"url":null,"abstract":"Regulatory affairs are a new profession that can be developed for the controlling the safety, quality and efficacy of the drug products by submitting the investigational new drug application (IND) and new drug application (NDA) to regulatory authority. The whole process may be done in conscious manner in order to release a safe drug product to protect the public from toxic effects of drugs during and after the usage of drugs. The main intention of this article was to aware the peoples towards the role of regulatory affairs department, requirements for new drug approval and the involvement of the regulatory professionals in this process as well as how crucial it is to perform and monitor the clinical and nonclinical trials of the drug before marketing the drug.","PeriodicalId":12614,"journal":{"name":"Future Journal of Pharmaceuticals and Health Sciences","volume":"10 12","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Review on regulatory affairs and regulatory requirements for drug approval\",\"authors\":\"Kishore Bandarapalle, R. K. Kumarachari, Kamasani Teja Sri, Boyalapalli Neeraja, Chejarla Likhitha, Krishna Chaitanya, C. Y. Bhargavi\",\"doi\":\"10.26452/fjphs.v4i1.550\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Regulatory affairs are a new profession that can be developed for the controlling the safety, quality and efficacy of the drug products by submitting the investigational new drug application (IND) and new drug application (NDA) to regulatory authority. The whole process may be done in conscious manner in order to release a safe drug product to protect the public from toxic effects of drugs during and after the usage of drugs. The main intention of this article was to aware the peoples towards the role of regulatory affairs department, requirements for new drug approval and the involvement of the regulatory professionals in this process as well as how crucial it is to perform and monitor the clinical and nonclinical trials of the drug before marketing the drug.\",\"PeriodicalId\":12614,\"journal\":{\"name\":\"Future Journal of Pharmaceuticals and Health Sciences\",\"volume\":\"10 12\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Journal of Pharmaceuticals and Health Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.26452/fjphs.v4i1.550\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Journal of Pharmaceuticals and Health Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26452/fjphs.v4i1.550","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

监管事务是一种新的职业,通过向监管机构提交新药研究申请(IND)和新药申请(NDA)来控制药品的安全、质量和疗效。整个过程可以有意识地进行,以发布安全的药物产品,保护公众在用药期间和用药后免受药物毒性的影响。本文的主要目的是让人们了解监管事务部门的作用、新药审批的要求、监管专业人员在这一过程中的参与,以及在药品上市前对药品进行临床和非临床试验并对其进行监测的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A Review on regulatory affairs and regulatory requirements for drug approval
Regulatory affairs are a new profession that can be developed for the controlling the safety, quality and efficacy of the drug products by submitting the investigational new drug application (IND) and new drug application (NDA) to regulatory authority. The whole process may be done in conscious manner in order to release a safe drug product to protect the public from toxic effects of drugs during and after the usage of drugs. The main intention of this article was to aware the peoples towards the role of regulatory affairs department, requirements for new drug approval and the involvement of the regulatory professionals in this process as well as how crucial it is to perform and monitor the clinical and nonclinical trials of the drug before marketing the drug.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信